Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
09-01-04 Drugs used in autoimmune thrombocytopenic purpura
| Anagrelide |
|
Formulary
|
Capsules 500 micrograms Effective contraception required during treatment. |
 MHRA: Xagrid (anagrelide hydrochloride): Risk of thrombosis, including cerebral infarction, if treatment discontinued abruptly. [also applicable to generic forms] |
|
| Avatrombopag Doptelet® |
|
Formulary
|
Tablets 20mg Specialist initiation only. |
 NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure NICE TA853: Avatrombopag for treating primary chronic immune thrombocytopenia |
|
|
| Caplacizumab Cablivi® |
|
Formulary
|
Solution for injection 10mg Specialist initiation only. |
|
NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura |
|
|
| Eltrombopag Revolade® |
|
Formulary
|
Tablets 25mg, 50mg Ensure effective contraception during treatment. |
|
MHRA: Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results NICE TA293: Eltrombopag for treating chronic immune thrombocytopenia |
|
| Fostamatinib TAVLESSE ® |
|
Formulary
|
Film coated tablets, 100mg, 150mg Specialist initiation only. Manufacturer advises effective contraception during and for at least 1 month after stopping treatment in females of childbearing potential. |
|
NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia |
|
|
| Lusutrombopag Mulpleo® |
|
Formulary
|
Film coated tablets 3mg Specialist initiation only. |
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
|
|
| Romiplostim Nplate® |
|
Formulary
|
Injection 250 micrograms |
|
NICE TA221: Romiplostim for the treatment of chronic immune thrombocytopenia |
|
|
Links
- LSCMMG: Bariatric surgery guidelines for prescribing of vitamins and nutritional supplements: Position Statement
- LSCMMG: Gluten-Free food products: Position Statement
- LSCMMG: Oral Nutritional Supplements in Primary Care
- LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children
- LSCMMG: Rituximab Intravenous Infusion for the Treatment of Autoimmune Haemolytic Anaemia (AIHA) in Adults NMR
- LSCMMG: Rituximab Intravenous Infusion For treatment of Idiopathic Thrombocytopenia Purpura (ITP) in adults NMR
- MHRA Drug Safety Update July 2017: Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results
- MHRA: Eltrombopag (Revolade): reports of interference with bilirubin and creatinine test results
- MHRA: Rituximab: screen for hepatitis B virus before treatment
- MHRA: Xagrid (anagrelide hydrochloride): Risk of thrombosis, including cerebral infarction, if treatment discontinued abruptly. [also applicable to generic forms]
- NICE CG32: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition
- NICE NG20: Coeliac disease: recognition, assessment and management
- NICE NG203: Chronic kidney disease: assessment and management
- NICE NG617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
- NICE TA221: Romiplostim for the treatment of chronic immune thrombocytopenia
- NICE TA221: Thrombocytopenic purpura - romiplostim
- NICE TA293: Eltrombopag for treating chronic immune thrombocytopenia
- NICE TA382: Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal)
- NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
- NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
- NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
- NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
- NICE TA667: Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura
- NICE TA743: Crizanlizumab for preventing sickle cell crises in sickle cell disease
- NICE TA759: Fostamatinib for treating refractory chronic immune thrombocytopenia
- NICE TA835: Fostamatinib for treating refractory chronic immune thrombocytopenia
- NICE TA835:Fostamatinib for treating refractory chronic immune thrombocytopenia
- NICE TA853 Avatrombopag for treating primary chronic immune thrombocytopenia
- NICE TA853: Avatrombopag for treating primary chronic immune thrombocytopenia
- NICE TAG 293: Eltrombopag for treating chronic ITP